Comprehensive review of multidimensional biomarkers in the ShangHai At Risk for Psychosis (SHARP) program for early psychosis identification

被引:2
|
作者
Zhang, TianHong [1 ]
Xu, LiHua [2 ]
Tang, XiaoChen [2 ]
Wei, YanYan [2 ]
Hu, YeGang [2 ]
Cui, HuiRu [2 ]
Tang, YingYing [2 ]
Li, ChunBo [2 ]
Wang, JiJun [2 ,3 ,4 ]
机构
[1] Shanghai Jiaotong Univ Sch Med, Shanghai Engn Res Ctr Intelligent Psychol Evaluat, Shanghai Mental Hlth Ctr, Shanghai Key Lab Psychot Disorders, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Sch Med, Shanghai Key Lab Psychot Disorders, Shanghai, Peoples R China
[3] Chinese Acad Sci, CAS Ctr Excellence Brain Sci & Intelligence Techno, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Inst Psychol & Behav Sci, Shanghai, Peoples R China
来源
PSYCHIATRY AND CLINICAL NEUROSCIENCES REPORTS | 2023年 / 2卷 / 04期
基金
中国国家自然科学基金;
关键词
biomarkers; clinical high risk; prediction; psychosis; CLINICAL HIGH-RISK; ULTRA-HIGH RISK; FOLLOW-UP; CALCULATOR; PRODROME; SCHIZOPHRENIA; SAMPLE; CHINA;
D O I
10.1002/pcn5.152
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Psychosis is recognized as one of the largest contributors to nonfatal health loss, and early identification can largely improve routine clinical activity by predicting the psychotic course and guiding treatment. Clinicians have used the clinical high-risk for psychosis (CHR) paradigm to better understand the risk factors that contribute to the onset of psychotic disorders. Clinical factors have been widely applied to calculate the individualized risks for conversion to psychosis 1-2 years later. However, there is still a dearth of valid biomarkers to predict psychosis. Biomarkers, in the context of this paper, refer to measurable biological indicators that can provide valuable information about the early identification of individuals at risk for psychosis. The aim of this paper is to critically review studies assessing CHR and suggest possible biomarkers for application of prediction. We summarized the studies on biomarkers derived from the findings of the ShangHai at Risk for Psychosis (SHARP) program, including those that are considered to have the most potential. This comprehensive review was conducted based on expert opinions within the SHARP research team, and the selection of studies and results presented in this paper reflects the collective expertise of the team in the field of early psychosis identification. The three dimensions with potential candidates include neuroimaging dimension of brain structure and function, electrophysiological dimension of event-related potentials (ERPs), and immune dimension of inflammatory cytokines and complement proteins, which proved to be useful in supporting the prediction of psychosis from the CHR state. We suggest that these three dimensions could be useful as risk biomarkers for treatment optimization. In the future, when available for the integration of multiple dimensions, clinicians may be able to obtain a comprehensive report with detailed information of psychosis risk and specific indications about preferred prevention.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Biomarkers in psychosis: an approach to early identification and individualized treatment
    Mirzakhanian, Heline
    Singh, Fiza
    Cadenhead, Kristin S.
    BIOMARKERS IN MEDICINE, 2014, 8 (01) : 51 - 57
  • [2] Prediction of transition to psychosis in patients with a clinical high risk for psychosis: a systematic review of methodology and reporting
    Studerus, E.
    Ramyead, A.
    Riecher-Rossler, A.
    PSYCHOLOGICAL MEDICINE, 2017, 47 (07) : 1163 - 1178
  • [3] Using the K-SADS psychosis screen to identify people with early psychosis or psychosis risk syndromes
    Tsuji, Thomas
    Phalen, Peter
    Rouhakhtar, Pamela Rakhshan
    Millman, Zachary
    Bussell, Kristin
    Thompson, Elizabeth
    Demro, Caroline
    Roemer, Caroline
    Reeves, Gloria
    Schiffman, Jason
    CLINICAL CHILD PSYCHOLOGY AND PSYCHIATRY, 2019, 24 (04) : 809 - 820
  • [4] Neurocognition in the Psychosis Risk Syndrome: A Quantitative and Qualitative Review
    Giuliano, Anthony J.
    Li, Huijun
    Mesholam-Gately, Raquelle I.
    Sorenson, Shannon M.
    Woodberry, Kristen A.
    Seidman, Larry J.
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (04) : 399 - 415
  • [5] Psychosis risk screening: A systematic review
    Kline, Emily
    Schiffman, Jason
    SCHIZOPHRENIA RESEARCH, 2014, 158 (1-3) : 11 - 18
  • [6] Calculating individualized risk components using a mobile app-based risk calculator for clinical high risk of psychosis: findings from ShangHai At Risk for Psychosis (SHARP) program
    Zhang, TianHong
    Xu, LiHua
    Li, HuiJun
    Woodberry, Kristen A.
    Kline, Emily R.
    Jiang, Jian
    Cui, HuiRu
    Tang, YingYing
    Tang, XiaoChen
    Wei, YanYan
    Hui, Li
    Lu, Zheng
    Cao, LiPing
    Li, ChunBo
    Niznikiewicz, Margaret A.
    Shenton, Martha E.
    Keshavan, Matcheri S.
    Stone, William S.
    Wang, JiJun
    PSYCHOLOGICAL MEDICINE, 2021, 51 (04) : 653 - 660
  • [7] Selective Review of Neuroimaging Findings in Youth at Clinical High Risk for Psychosis: On the Path to Biomarkers for Conversion
    Ellis, Justin K.
    Walker, Elaine F.
    Goldsmith, David R.
    FRONTIERS IN PSYCHIATRY, 2020, 11
  • [8] Early traumatic experiences, perceived discrimination and conversion to psychosis in those at clinical high risk for psychosis
    Stowkowy, Jacqueline
    Liu, Lu
    Cadenhead, Kristin S.
    Cannon, Tyrone D.
    Cornblatt, Barbara A.
    McGlashan, Thomas H.
    Perkins, Diana O.
    Seidman, Larry J.
    Tsuang, Ming T.
    Walker, Elaine F.
    Woods, Scott W.
    Bearden, Carrie E.
    Mathalon, Daniel H.
    Addington, Jean
    SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY, 2016, 51 (04) : 497 - 503
  • [9] Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review
    Farris, Megan S.
    Shakeel, Mohammed K.
    Addington, Jean
    SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY, 2020, 55 (05) : 527 - 537
  • [10] The impact of inflammation on neurocognition and risk for psychosis: a critical review
    Kogan, Sophia
    Ospina, Luz H.
    Mittal, Vijay A.
    Kimhy, David
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2020, 270 (07) : 793 - 802